Abstract
Abstract Molecular farming in plants provides an inexpensive and convenient way to produce biopharmaceutical molecules and other valuable proteins on a large scale. Proof of principle has been demonstrated for a large number of recombinant human proteins, subunit vaccines and antibodies, and detailed cost evaluations have been described for the production of technical proteins in maize. In terms of biosafety, plants have several advantages over traditional production systems, such as the absence of endotoxins, human pathogens and oncogenic DNA sequences. However, other biosafety concerns remain to be addressed. These not only reflect the quality and safety of the final product, but also the wider effects of molecular farming on health and the environment. In this review we discuss the technological basis of molecular farming in plants and identify potential biosafety risks: transgene spread in the environment, recombinant protein accumulation in the ecosystem, contamination of food and feed chains with transgenes and their products, and product quality and safety.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.